Transcatheter therapies for structural heart diseases
JoVE will publish text articles after the peer review, which on average takes two months after the manuscript submission. We will film and add corresponding videos to our website when laboratories and facilities in affected areas reopen.
Department of General and Interventional Cardiology, Helios Klinikum Erfurt, Germany
Prof. Dr. med Alexander Lauten is Head of the Department of General and Interventional Cardiology at Helios Klinikum…
Department of Cardiology, Campus Benjamin Franklin, Charité Medical University Berlin, Germany
Dr. Brunilda Alushi is an MD and a PhD in Molecular Medicine, from the University of Turin, Italy, and specialist in…
The incidence of valvular heart diseases, which are responsible for a high rate of morbidity and mortality worldwide, increases with age. Until recently, the only treatment option was surgery. With the advent of transcatheter solutions, a result of impressive technical developments in the field of medical devices, the landscape of treatment strategies for patients with valvular heart diseases has dramatically improved. Today, numerous available devices offer percutaneous treatment options for these severe conditions while avoiding surgery. Whereas the transcatheter aortic valve replacement (TAVR/TAVI) is a well-established technique, now expanding to low risk patients, interventional treatment of mitral and tricuspid valve pathologies is more complex and requires a patient-tailored approach, strongly based on multimodality imaging techniques like two -and three-dimensional echocardiography, cardiac computed tomography, and MRI.
In this collection, we will focus on recent developments in the field of interventional treatment solutions for patients with valvular heart diseases, while discussing the technical aspects and challenges related to patient and device selection, especially for mitral and tricuspid valve pathologies.